Clinical Practices of PSMA-Targeted Agents in Prostate Cancer

Clinical oncologists share their best practices for the utilization of PSMA-targeted agents in patients with prostate cancer.

EP: 1.The Evolution of Imaging Techniques in Prostate Cancer

EP: 2.The Utility of PSMA PET in Prostate Cancer

EP: 3.Clinical Development of PSMA-Targeted Therapies

Now Viewing

EP: 4.Clinical Practices of PSMA-Targeted Agents in Prostate Cancer

EP: 5.Multidisciplinary Approaches in PSMA PET for Prostate Cancer

EP: 6.Patient Profile 1: A 51-Year-Old Man with High-Risk Localized Prostate Cancer

EP: 7.PSMA PET Imaging and Clinical Perspectives from Patient Profile 1

EP: 8.LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

EP: 9.An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

EP: 10.SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer

EP: 11.Patient Profile 2: A 62-Year-Old Man with Recurrent Prostate Cancer

EP: 12.Patient Profile 3: A 67-Year-Old Male with Recurrent Prostate Cancer

EP: 13.Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

Related Videos

Related Content

Advertisement

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor

More than 80% of patients in both groups had a full recovery of testosterone.

April 26th 2025

TikTok, social media does more harm than good for prostate cancer education

Patrick Campbell

Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.

Related Content

Advertisement

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor

More than 80% of patients in both groups had a full recovery of testosterone.

April 26th 2025

TikTok, social media does more harm than good for prostate cancer education

Patrick Campbell

Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.